Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials
Objective: Mirabegron, a β3-adrenoceptor agonist, has been shown to be effective and safe in the treatment of overactive bladder (OAB). The aim of this study was to assess the efficacy and safety of mirabegron (50 mg) versus placebo in Taiwanese patients with OAB. Materials and patients: This was a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2015-03-01
|
| Series: | Urological Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1879522615000020 |